AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 18254985
Drug: Tomato juice
RxNorm normalized name: TOMATO JUICE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tomato juice (330 ml per day for 2 weeks)
Trial: 12843036
Drug: Presence of
RxNorm normalized name: Dna Plasmid Expressing Diphtheria Toxin Triggered By The Presence Of Oncofetal Gene H19
DrugBank: Inodiftagene vixteplasmid (DB16017)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Presence of staphylococcal plasmid encoding multiple antibiotic resistance traits
Trial: 10374223
Drug: Initial gestagen
RxNorm normalized name: Betagen brand of Betamethasone and Gentamicin Topical Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Initial gestagen treatment (5 mg medroxyprogesterone acetate, twice daily, for 10 days)
Trial: 10374223
Drug: Continuous combined
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous combined hormone replacement therapy without initial gestagen treatment
Trial: 10374223
Drug: Initial gestagen
RxNorm normalized name: Betagen brand of Betamethasone and Gentamicin Topical Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Initial gestagen treatment
Trial: 8708877
Drug: Behavioral intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Behavioral intervention (6-week group treatment providing nutritional education and management strategies)
Trial: 2065411
Drug: No alfentanil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No alfentanil administered (Group 4)
Trial: 31982887
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of monochromatic 308-nm excimer light (MEL) and topical calcipotriol
Trial: 31982887
Drug: Topical calcipotriol
RxNorm normalized name: calcipotriol
DrugBank: Calcipotriol (DB02300)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical calcipotriol alone
Trial: 31982887
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of MEL and topical calcipotriol
Trial: 29960800
Drug: MenACWY-TT and
RxNorm normalized name: meningococcal conjugate quadrivalent, MenACWY-TT (MCV4)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MenACWY-TT and Tdap co-administered at Month 0 (Co-ad group)
Trial: 29960800
Drug: MenACWY-TT and
RxNorm normalized name: meningococcal conjugate quadrivalent, MenACWY-TT (MCV4)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MenACWY-TT and Tdap co-administered
Trial: 22633362
Drug: Intravesical mitomycin
RxNorm normalized name: Mitomycin
DrugBank: Mitomycin (DB00305)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravesical mitomycin C (MMC) 40 mg/40 ml, three instillations per week for 2 weeks (group 2)
Trial: 22633362
Drug: Intravesical mitomycin
RxNorm normalized name: Mitomycin
DrugBank: Mitomycin (DB00305)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravesical mitomycin C (MMC) 40 mg/40 ml, one instillation per week for 6 weeks (group 1)
Trial: 17164834
Drug: In-center daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In-center daily HD (1.5-2.75 h, 6 days/week)
Trial: 17164834
Drug: In-center daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In-center daily HD
Trial: 12050241
Drug: Growth hormone
RxNorm normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Growth hormone (GH) at a dose of 0.005-0.010 mg/kg.d for 6 months
Trial: 10760843
Drug: Oral solution
RxNorm normalized name: Oral Solution
DrugBank: Sodium citrate (DB09154)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral solution (5 mg)
Trial: 10760843
Drug: Oral tablet
RxNorm normalized name: Oral Tablet
DrugBank: Sodium citrate (DB09154)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral tablet formulation (5 mg)
Trial: 10760843
Drug: Intravenous infusion
RxNorm normalized name: intravenous infusion pump accessory
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous infusion (5 mg)
Trial: 2147698
Drug: Clobetasol propionate
RxNorm normalized name: Clobetasol Propionate
DrugBank: Clobetasol propionate (DB01013)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Clobetasol propionate ointment 0.05%
Trial: 343032
Drug: 400 mg
RxNorm normalized name: mesna 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg of ibuprofen
Trial: 343032
Drug: 800 mg
RxNorm normalized name: bran 800 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 800 mg of ibuprofen
Trial: 343032
Drug: 650 mg
RxNorm normalized name: bran 650 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 650 mg of aspirin
Trial: 343032
Drug: 65 mg
RxNorm normalized name: opium 65 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 65 mg of propoxyphene HCl
Trial: 31941553
Drug: Wearing habitual
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Wearing habitual correction (cc)
Trial: 31941553
Drug: Wearing habitual
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Wearing habitual correction (cc) for IED detection
Trial: 31464100
Drug: Nutritional care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nutritional care as per the algorithm (oral supplements, nasogastric feeds, and/or parenteral nutrition)
Trial: 27525497
Drug: Conservative treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conservative treatment (supination sugar-tong splinting)
Trial: 27525497
Drug: Operative treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Operative treatment (DRUJ transfixation)
Trial: 27525497
Drug: Operative treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Operative treatment (arthroscopic triangular fibrocartilage complex repair)
Trial: 19882460
Drug: Drug users
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug users not participating in the research
Trial: 12213743
Drug: Intravenous triiodothyronine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous triiodothyronine administration (bolus followed by 6 hours infusion)
Trial: 8591798
Drug: Single-dose L-dopa/benserazide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-dose L-dopa/benserazide (300/75 mg)
Trial: 2677988
Drug: Radiation therapy
RxNorm normalized name: Sensitizers used in photodynamic/radiation therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Radiation therapy for bone metastasis
Trial: 2677988
Drug: Radiation therapy
RxNorm normalized name: Sensitizers used in photodynamic/radiation therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Radiation therapy for lung cancer patients with bone metastasis
Trial: 934556
Drug: Prophylactic antibiotics
RxNorm normalized name: polylactic acid-polyglycolic acid copolymer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prophylactic antibiotics alone
Trial: 934556
Drug: T-tube suction
RxNorm normalized name: T-5224
DrugBank: T-5224 (DB05998)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: T-tube suction drainage and prophylactic antibiotics in combination
Trial: 31739177
Drug: <7/7 intended
FDA approved: no
EMA approved: no
PMDA approved: no
Description: <7/7 intended doses (ID)
Trial: 19622782
Drug: Low-dose rosiglitazone
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose rosiglitazone (4 mg/day)
Trial: 19622782
Drug: High-dose rosiglitazone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose rosiglitazone (8 mg/day)
Trial: 19622782
Drug: High-dose metformin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose metformin (2,000 mg/day)
Trial: 19622782
Drug: Low-dose combination
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose combination rosiglitazone-metformin therapy (4 mg + 1,000 mg/day)
Trial: 19622782
Drug: High-dose rosiglitazone-metformin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose rosiglitazone-metformin combination therapy (8 mg + 2,000 mg/day)
Trial: 7488475
Drug: Extradural morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extradural morphine 2 mg (group M)
Trial: 7488475
Drug: 2% lignocaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2% lignocaine 10 ml (group L)
Trial: 7488475
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of morphine 2 mg and 2% lignocaine 10 ml (group ML)
Trial: 8349939
Drug: Bumetanide (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bumetanide (2 mg)
Trial: 6167346
Drug: Lower dosage
RxNorm normalized name: flowers
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lower dosage of vinblastine (0.3 mg/kg)
Trial: 6167346
Drug: Four courses
RxNorm normalized name: Four-Way
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Four courses of remission induction therapy
Trial: 26375942
Drug: Citalopram 20
RxNorm normalized name: citalopram 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Citalopram 20 mg once daily for 2 weeks followed by raltegravir 400 mg twice daily for 5 days
Trial: 26375942
Drug: Raltegravir 400
RxNorm normalized name: raltegravir 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Raltegravir 400 mg twice daily for 5 days
Trial: 22650964
Drug: Oral administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral administration of vitamin B12 (1 mg/day in weeks 1-8 and 1 mg/week in weeks 9-52)
Trial: 22650964
Drug: Intramuscular administration
RxNorm normalized name: Japanese Encephalitis vaccine for intramuscular administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular administration of vitamin B12 (1 mg on alternate days in weeks 1 and 2, 1 mg/week in weeks 3-8, and 1 mg/month in weeks 9-52)
Trial: 22650964
Drug: Both oral
RxNorm normalized name: Bothrops atrox venom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both oral and intramuscular administration
Trial: 15067411
Drug: Optical rhinometry
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Optical rhinometry during negative provocation tests with control solution
Trial: 11233800
Drug: Gemifloxacin (320
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gemifloxacin (320 mg orally for 7 days)
Trial: 11233800
Drug: Placebo (matched,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (matched, once daily for 7 days)
Trial: 8894914
Drug: Biofeedback-assisted relaxation
RxNorm normalized name: endothelium-derived relaxing factor
DrugBank: Nitric Oxide (DB00435)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Biofeedback-assisted relaxation therapy
Trial: 26281833
Drug: Standard dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard dose of 1.0 Gy applied in 6 fractions of 1.0 Gy twice weekly (total dose 6.0 Gy)
Trial: 26281833
Drug: Low single
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low single doses of 0.5 Gy applied in 12 fractions of 0.5 Gy three times weekly (total dose 6.0 Gy)
Trial: 19686527
Drug: MET +
RxNorm normalized name: Metformin
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: MET + Cognitive-Behavioral Therapy (CBT)
Trial: 17942927
Drug: Zanolimumab (human
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zanolimumab (human IgG1 antibody against CD4)
Trial: 15562884
Drug: Combined ibuprofen/pseudoephedrine/chlorpheniramine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined ibuprofen/pseudoephedrine/chlorpheniramine (200/30/2 mg)
Trial: 15562884
Drug: Combined ibuprofen/pseudoephedrine/chlorpheniramine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined ibuprofen/pseudoephedrine/chlorpheniramine (400/60/4 mg)
Trial: 15562884
Drug: Combined pseudoephedrine/chlorpheniramine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined pseudoephedrine/chlorpheniramine (30/2 mg)
Trial: 11146707
Drug: Combined outreach
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined outreach initiative for pneumococcal and influenza vaccines
Trial: 11146707
Drug: Combined outreach
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined outreach initiative targeted to people who had never received the pneumococcal vaccine or who had not received the influenza vaccine in the previous year
Trial: 7870348
Drug: Controlled Protein
RxNorm normalized name: protein C
DrugBank: Protein C (DB11312)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Controlled Protein Diet (CPD) of 1 g protein/kg ideal body-weight/day
Trial: 7870348
Drug: Low-Protein Diet
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-Protein Diet (LPD) of 0.6 g protein/kg ideal body-weight/day
Trial: 28166654
Drug: VM202 (64
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VM202 (64 mg) administered by intramuscular injections on days 0, 7, 14, and 21.
Trial: 28166654
Drug: VM202 (64
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VM202 (64 mg) administered by intramuscular injections.
Trial: 28166654
Drug: VM202 treatment.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VM202 treatment.
Trial: 21931228
Drug: Tartary buckwheat
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tartary buckwheat cookies (359.7 mg rutin equivalents/day)
Trial: 21931228
Drug: Common buckwheat
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Common buckwheat cookies (16.5 mg rutin equivalents/day)
Trial: 11054354
Drug: Intradermal vaccination
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intradermal vaccination (5 microgram of recombinant hepatitis B vaccine, Engerix B) every 2 weeks up to a peak Ab titer of 1,000 IU/L or greater or 52 doses
Trial: 11054354
Drug: Intramuscular vaccination
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular vaccination (40 microgram at 0, 1, 2, and 6 months)
Trial: 11054354
Drug: Intramuscular vaccination
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular vaccination with peak Ab titer of 1,000 IU/L or greater
Trial: 8866093
Drug: Aprotinin (high
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aprotinin (high doses)
Trial: 1339712
Drug: Allopurinol (oral,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Allopurinol (oral, preoperatively)
Trial: 6391936
Drug: Cisapride 5
RxNorm normalized name: cisapride 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cisapride 5 mg
Trial: 6391936
Drug: Cisapride 4
RxNorm normalized name: Cisapride
DrugBank: Cisapride (DB00604)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cisapride 4 mg (IV)
Trial: 6391936
Drug: Cisapride 8
RxNorm normalized name: Cisapride
DrugBank: Cisapride (DB00604)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cisapride 8 mg (IV)
Trial: 6391936
Drug: Metoclopramide 10
RxNorm normalized name: metoclopramide 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metoclopramide 10 mg (IV)
Trial: 31608548
Drug: Basal insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Basal insulin glargine 100 U/mL (Gla-100)
Trial: 29498534
Drug: Nocturnal dexmedetomidine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nocturnal dexmedetomidine (0.2 μg/kg/h, titrated by 0.1 μg/kg/h every 15 min until a goal Richmond Agitation and Sedation Scale score of -1 or maximum rate of 0.7 μg/kg/h)
Trial: 22668427
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg allicin adhesive tablets
Trial: 19910620
Drug: Single-injection peribulbar
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-injection peribulbar anesthesia with a 16-mm needle
Trial: 19910620
Drug: Double-injection peribulbar
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Double-injection peribulbar anesthesia with a 25-mm needle
Trial: 8140047
Drug: Ondansetron 8
RxNorm normalized name: ondansetron 8 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ondansetron 8 mg administered orally
Trial: 8140047
Drug: Ondansetron 8
RxNorm normalized name: ondansetron 8 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ondansetron 8 mg administered to the colon via nasogastric intubation
Trial: 8140047
Drug: Ondansetron 8
RxNorm normalized name: ondansetron 8 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ondansetron 8 mg administered rectally using a retention enema
Trial: 8140047
Drug: Nonparenteral routes
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nonparenteral routes (oral, colonic, rectal)
Trial: 30621622
Drug: Low-dose aspirin
RxNorm normalized name: low-dose aspirin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-dose aspirin once per day (Group A)
Trial: 30621622
Drug: Low-dose aspirin
RxNorm normalized name: low-dose aspirin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-dose aspirin and 4.0 g of ecabet sodium (Group B)
Trial: 26742006
Drug: Tamoxifen 40
RxNorm normalized name: tamoxifen 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tamoxifen 40 mg daily for 2 or 5 years
Trial: 26742006
Drug: Tamoxifen treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tamoxifen treatment in patients with triple-negative and AR+ tumours
Trial: 26742006
Drug: Tamoxifen treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tamoxifen treatment in patients with AR- tumours
Trial: 22583535
Drug: Drinking reduction
RxNorm normalized name: reductic acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drinking reduction strategies during treatment
Trial: 17242082
Drug: Magnetic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Magnetic therapy (n = 81)
Trial: 17242082
Drug: Sham therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham therapy (n = 84)
Trial: 16075030
Drug: Blood pressure
RxNorm normalized name: Blood Pressure Kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Blood pressure lowering using a fixed low-dose combination of perindopril and indapamide
Trial: 12469525
Drug: Screening-tools for
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Screening-tools for early identification and treatment of sleep-related breathing disorders
Trial: 10440565
Drug: Aspirin 150
RxNorm normalized name: aspirin 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin 150 mg/d
Trial: 479352
Drug: Aminoglutethimide (AG)
RxNorm normalized name: Aminoglutethimide
DrugBank: Aminoglutethimide (DB00357)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aminoglutethimide (AG) 1250 mg in divided doses
Trial: 25282598
Drug: Buprenorphine/naloxone stabilization
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Buprenorphine/naloxone stabilization and taper
Trial: 19052048
Drug: CT group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CT group (low-dose CT screening)
Trial: 12236276
Drug: Nitrofurantoin 100
RxNorm normalized name: nitrofurantoin 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nitrofurantoin 100 mg four times daily for three days
Trial: 7813225
Drug: Low-dose biphasic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-dose biphasic oral contraceptive (25 micrograms desogestrel and 40 micrograms ethinylestradiol for 7 days, followed by 125 micrograms desogestrel and 30 micrograms ethinylestradiol for 15 days)
Trial: 7813225
Drug: Diane-35 (2.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diane-35 (2.0 mg cyproterone acetate and 30 micrograms ethinylestradiol for 21 days)
Trial: 2628304
Drug: Centpropazine 120
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Centpropazine 120 mg and above
Trial: 2628304
Drug: Centpropazine 40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Centpropazine 40 mg daily
Trial: 2628304
Drug: Centpropazine 80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Centpropazine 80 mg daily
Trial: 624266
Drug: MAOI plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MAOI plus L-tryptophan
Trial: 31924256
Drug: Routine rehabilitation
RxNorm normalized name: Peace Out Acne Hero Routine KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Routine rehabilitation therapy
Trial: 16908730
Drug: Argatroban (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Argatroban (100 mug/kg bolus followed by 1 mug/kg/min infusion for 48 hours) combined with intravenous rtPA
Trial: 10715521
Drug: pa vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: pa vaccine
Trial: 31529471
Drug: Fluorouracil 5%
RxNorm normalized name: FLUOROURACIL 5% CREAM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluorouracil 5% cream
Trial: 29862491
Drug: Methyl aminolaevulinate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methyl aminolaevulinate photodynamic therapy (MAL-PDT)
Trial: 24918567
Drug: Ingenol mebutate
RxNorm normalized name: Ingenol Mebutate
DrugBank: Ingenol mebutate (DB05013)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ingenol mebutate 0.015% gel
Trial: 28888286
Drug: Information treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Information treatment about funding opportunities for, and returns to, higher education (25-minute session)
Trial: 26094929
Drug: 2 mg
RxNorm normalized name: iodine 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg eszopiclone per day
Trial: 10854004
Drug: Chronic oestrogen
RxNorm normalized name: estrogens
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chronic oestrogen replacement therapy (ERT) 0.625 mg/day
Trial: 10854004
Drug: Combined oestrogen
RxNorm normalized name: estrogens
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined oestrogen and progestogen replacement therapy (HRT) ERT plus continuous medroxyprogesterone acetate 5 mg/day